Earnings Summary

ORAMED PHARMACEUTICALS INC’s revenue jumped 388.8% since last year same period to $0.61Mn in the Q1 2017. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated 0.16% jump in its revenue since last 3-months.

ORAMED PHARMACEUTICALS INC’s net profit fell -75.08% since last year same period to $-3.18Mn in the Q1 2017. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -20.75% fall in its net profits since last 3-months.

ORAMED PHARMACEUTICALS INC’s net profit margin jumped 64.18% since last year same period to -520.95% in the Q1 2017. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -20.55% fall in its net profit margins since last 3-months.

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a -23.28% fall from last quarter’s estimates.

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -0.24.

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the ORAMED PHARMACEUTICALS INC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ORAMED PHARMACEUTICALS INC’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ORAMED PHARMACEUTICALS INC’s return on equity (ROE) stands at -0.24.